Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, Noguchi M, Koike M, Sakamoto J, Oba K, Komatsu N. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group. Oncology. 2017. [Epub ahead of print]
Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, Sano T, Ohkawara H, Kimura S, Shichishima-Nakamura A, Nakamura Y, Shikama Y, Mori T, Mason PJ, Bessler M, Morishita S, Komatsu N, Shide K, Shimoda K, Koide S, Aoyama K, Oshima M, Iwama A, Takeishi Y. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Advances. 2017;1(15):1001-15.
Sunami Y, Araki M, Kan S, Ito A, Hironaka Y, Imai M, Morishita S, Ohsaka A, Komatsu N. Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. J Biol Chem. 2017;292(7):2815-29.
Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma. 2017:1-8.
Sakurai H, Harada Y, Ogata Y, Kagiyama Y, Shingai N, Doki N, Ohashi K, Kitamura T, Komatsu N, Harada H. Overexpression of RUNX1 short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms. Blood Advances. 2017;1(18):1382-6.
Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria. Am J Hematol. 2017;92(7):E128-e30.
Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. Int J Hematol. 2017;105(3):309-17.
Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M. A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). Am J Hematol. 2017;92(12):1324-32.
Kitahara H, Maruyama D, Maeshima AM, Makita S, Miyamoto KI, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Tajima K, Terauchi T, Kurihara H, Taniguchi H, Komatsu N, Tobinai K. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. Ann Hematol. 2017;96(3):411-20.
Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HF. Prevalence of Slow-growth Vancomycin Non-susceptibility In Methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2017;61(11):e00452-17.
Iriyama N, Tokuhira M, Takaku T, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Hatta Y, Kizaki M, Komatsu N, Asou N, Kawaguchi T. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group. Leuk Res. 2017;54:55-8.
Ikuta K, Hatayama M, Addo L, Toki Y, Sasaki K, Tatsumi Y, Hattori A, Kato A, Kato K, Hayashi H, Suzuki T, Kobune M, Tsutsui M, Gotoh A, Aota Y, Matsuura M, Hamada Y, Tokuda T, Komatsu N, Kohgo Y. Iron overload patients with unknown etiology from national survey in Japan. Int J Hematol. 2017;105(3):353-60.
Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol.2017;96(10):1653-65.
Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res.2017;23(14):3499-509.
Tsukune Y, Sasaki M, Odajima T, Sunami K, Takei T, Moriuchi Y, Iino M, Isoda A, Nakaya A, Muta T, Miyake T, Miyazaki K, Shimizu T, Nakajima K, Igarashi A, Nagafuji K, Kurihara T, Aoyama T, Sugimori H, Komatsu N. Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan. Blood Cancer J. 2017; 7(12): 631.
Saito A, Isoda A, Kojima M, Yokohama A, Tsukune Y, Sasaki M, Ito S, Ohtsu A, Koike M, Murayama K, Moriya K, Tamura H, Matsumoto M, Nakahashi H, Tanosaki S, Sakura T, Kawamura T, Miyanaga T, Nakamura N, Murakami H, Handa H, Tsukamoto N. Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan. Int J Hematol. 2017; 106(5): 681-690.
総説
Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol. 2017;105(6):743-7.
Araki M, Komatsu N. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. Cancer Sci. 2017;108(10):1907-12.
Watanabe N, Yasuda H, Morishita S, Aota Y, Tomomatsu J, Tanaka M, Ohsaka A, Komatsu N. Richter's Syndrome with Hypercalcemia Induced by Tumor-Associated Production of Parathyroid Hormone-Related Peptide. Case Rep Oncol. 2017;10(1):123-6.
Sekiguchi Y, Wakabayashi M, Takizawa H, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y, Komatsu N, Noguchi M. A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission. J Clin Exp Hematop. 2017;57(2):79-81.
Sekiguchi Y, Takizawa H, Inano T, Fukuda Y, Wakabayashi M, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y, Komatsu N, Noguchi M. Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD). Int J Hematol.2017;106(4):581-7.
Ikeda K, Ueda K, Sano T, Ogawa K, Ikezoe T, Hashimoto Y, Morishita S, Komatsu N, Ohto H, Takeishi Y. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation. Intern Med. 2017;56(13):1705-10.
Iizuka K, Ando J, Masuda A, Ochiai T, Tomomasa R, Yasuda H, Takaku T, Ota Y, Yao T, Gotoh A, Komatsu N. Acute exacerbation of organizing pneumonia leading to sudden death in a patient with sarcoidosis-lymphoma syndrome. Rinsho Ketsueki. 2017;58(8):927-32.
Ando J, Masuda A, Iizuka K, Ochiai T, Shingai N, Yasuda H, Homma Y, Kobayashi E, Morishita E, Komatsu N. Factor XI deficiency as a result of a novel Tyr347Stop nonsense mutation in an elderly Japanese woman. Geriatr Gerontol Int. 2017;17(6):1029-31.
Sano K, Homma Y, Baba T, Ando J, Matsumoto M, Kobayashi H, Yuasa T, Kaneko K. Total hip arthroplasty via the direct anterior approach with Kerboull-type acetabular reinforcement device for an elderly female with factor XI deficiency. Sicot j. 2017;3:11.
海外学会発表
Tsukune Y, Sasaki M, Odajima T, Isoda A, Sumami K, Takei T, Taniguchi H, Iino M, Nakaya A, Muta T, Miyake T, Miyazaki K, Shimizu T, Nakajima K, Igarashi A, Nagafuji K, Kurihara T, Uchino Y, Komatsu N, Hepatitis B virus reactivation in multiple myeloma patients in the era of novel agents: a nationwide retrospective study in Japan. 16th International Myeloma Workshop,Delhi, India, March 2,2017.
Takei H, Mano S, Masubuchi N, Mizukami Y, Morishita S, Imai M, Edahiro Y, Hironaka Y, Nudejima M, Tsuneda S, Endo H, Nakamura S, Eto K, Ohsaka A, Araki M, Komatsu N, editors. Establishment of an in vitro model for the skewed megakaryopoiesis by calreticulin mutation in human cells. 22nd Congress of the European Hematology Association; 2017; Madrid; Spain.
Masubuchi N, Araki M, Hayashi E, Yang Y, Imai M, Kihara Y, Mizukami Y, Hironaka Y, Takei H, Edahiro Y, Ohsaka A, N. K, editors. Localization of Mutant Calreticulin in the Golgi Apparatus Is Required for Its Oncogenic Capacity. 59th Annual Meeting of the American Society of Hematology and Exposition; 2017; Atlanta, USA.
Sunakawa M, Tamura H, Ishibashi M, Sasaki M, Handa H, Imai Y, Tanaka J, Tanosaki S, Ito S, Inokuchi K. Clinical impact and possible immunosuppressive function of soluble B7-H1(PD-L1) in multiple myeloma. 16th International Myeloma Workshop, Delhi, March 3,2017.
Kaito Y, Tamura H, Soeda S, Asayama T, Ishibashi M, Sasaki M, Handa H, Imai Y, Tanaka J, Tanosaki S, Ito S, Inokuchi K. Serum soluble SLAMF7 with disease progression in multiple myeloma and may affect anti-SLAMF7 antibody therapy. 16th International Myeloma Workshop, Delhi, India,March 2,2017.
高橋直人, 中世古知昭, 脇田久, 得平道英, 三谷絹子, 野口雅章, 木村文彦, 三浦昌朋: DMR and TFR following 2-year consolidation by Nilotinib in patients with CML: STAT trial in Japan, 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月20日
若林睦, 関口康宣, 坂尻さくら, 杉元啓二, 瀧澤春子, 飯塚弘子, 小松則夫, 野口雅章: Retrospective analysis of AE and manage in 23 patients treated with bendamustine at our department. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
瀧澤春子, 関口康宣, 坂尻さくら, 杉元啓二, 若林睦, 飯塚弘子, 小松則夫, 野口雅章: ET was difficult to differentiate from PMF/early that was treated with ruxolitinib, to preleukemia. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
野口雅章, 小松則夫, 小池道明, 木崎昌弘, 片山直之, 土橋史明, 薄井紀子, 桐戸敬太: Clinical Performance Study of a novel JAK2V617F mutation quantitative kits for patients with Ph-MPN. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
舛井嘉大, 関口康宣, 坂尻さくら, 杉元啓二, 若林睦, 瀧澤春子, 飯塚弘子, 小松則夫, 野口雅章: A primary bone marrow low grade B-cell lymphoma. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日.
Tsukune Y, Sasaki M, Sunami K, Suzuki K, Taniguchi H, Iino M, Isoda A, Nakaya A, Muta T, Miyake T, Miyazaki K, Shimizu T, Nakajima K, Igarashi A, Nagafuji K, Kurihara T, Uchino Y, Komatsu N. HBV reactivation in MM patients in the novel agents era: A nationwide retrospective study in Japan., 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, Yoshihiro Hatta, Komatsu N, Asou N, Kizaki M, Kawaguchi T. Efficacy and safety of the reduced nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Shingai N, Harada Y, Sakurai H, Ogata Y, Akahane K, Nishio M, Doki N, Ohashi K, Hagihara M, Komatsu N, Harada H. Splicing factor mutations may define the phenotypes and disease evolution of MDS. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto K, Fujita H, Fujioka I, Hatta Y, Kizaki M, Komatsu N, Asou N, Kawaguchi T. The introduction of 2nd generation TKIs may reduce the prognostic impact of EUTOS high-risk patients. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Kinoshita R, Ishibashi M, Inokuchi K, Handa H, Sasaki M, Komatsu N, Imai Y, Tanaka N, Tanaka J, Tanosaki S, Ito S, Isoda A, Matsumoto M, Koike M, Tamura H. Evalution of staging and prognostic factors in multiple myeloma:KT-MM prognostic analysis. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Nakazato T, Iriyama N, Ishikawa M, Sato E, Takaku T, Fujioka I, Sugimoto K, Fujita H, Kizaki M, Komatsu N, Asou N, Tokuhira M, Kawaguchi T. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Masubuchi N, Araki M, Hayashi E, Yang Y, Imai M, Mizukami Y, Hironaka Y, Takei H, Morishita S, Kihara Y, Edahiro Y, Ohsaka A, Komatsu N. Engagement of mutant calreticulin and MPL in a cellular compartment is required for MPL activation. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Umezawa G, Ishibashi M, Tamura H, Asayama T, Kuribayashi-Hamada Y, Moriya K, Imai Y, Tanaka J, Handa H, Sasaki M, Tanosaki S, Ito S, Komatsu N, Inokuchi K. Clinical significance of CD86 soluble from and cell-surface expression in multiple myeloma patients. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
